Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus irinotecan versus standard chemotherapy in previously treated unresectable advanced EGFR-expressing colorectal cancer
2006-004849-42Phase 3Terminated
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, irinotecan and mitomycin c in colorectal cancer (CRC) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Overall survival. Started Jun 2007; status: terminated.
02
Drugs
cetuximabirinotecanmitomycin c
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-004849-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004849-42.